go-v.orgdoi

Neuroprotective agents in ischemic stroke: past failures and future opportunities

Jiangyong Min, Muhammad Umar Farooq, Philip B. Gorelick · Clinical Investigation · 2013

  • DOI 10.4155/cli.13.91
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2013

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2013

Abstract

Tissue plasminogen activator is the only US FDA-approved therapy for acute ischemic stroke treatment. There is a need for other therapies such as neuroprotective agents that can be used in acute ischemic stroke patients. Many neuroprotective agents have been shown to be promising after testing in animal models of acute stroke, but when tested in patients, efficacy signals are not consistent or safety challenges have been noted.

This review article will discuss different neuroprotective agents, including free-radical scavengers and antioxidants, NMDA-receptor antagonists, inflammatory cascade inhibitors and different ion channel blockers/modulators that have been tested in acute ischemic stroke. The review will also address the key reasons for their failure in clinical trials and provide recommendations to improve translation of basic science research into day-to-day clinical practice.

Open the resolved locator · 10.4155/cli.13.91

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 23:47 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.13.91
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.